Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 4/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122628 | 0.83 | AOC3 (0.47) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL731954 | 0.83 | IDO1 (0.48) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL1506598 | 0.83 | CA1 (0.50) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL7236788 | 0.80 | ALDH1A1 (0.49) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL8891278 | 0.78 | LMNA (0.56) | TDP1MAPK1ALDH1A1LMNAALOX15 | |
| SCHEMBL7043985 | 0.78 | CA1 (0.55) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL7837799 | 0.78 | ESR1 (0.56) | ALDH1A1LMNAHSD17B10ESR2MEN1 | |
| SCHEMBL3799108 | 0.78 | CA1 (0.55) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL6865347 | 0.77 | LMNA (0.49) | AOC3TDP1MAPK1ALDH1A1LMNA | |
| SCHEMBL5305755 | 0.76 | LTA4H (0.52) | AOC3TDP1ALDH1A1LTA4HKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-2007770-A1 | IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | AOC3 1620/4885TDP1 3617/4885MAPK1 1231/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | AOC3 2096/4885TDP1 3478/4885MAPK1 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.